We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genzyme Could Pay $175 Million as Part of FDA Consent Decree
Genzyme Could Pay $175 Million as Part of FDA Consent Decree
May 3, 2010
Genzyme expects to finish negotiations in the next quarter with the FDA on a consent decree, which may cost the company $175 million and set up a time
frame to move fill-finish operations out of its Allston, Mass., facility, which had been offline due to contamination.